Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SHR1459 in Healthy Volunteers
NCT03668509Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Sep 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of edralbrutinib in B cell malignancies and autoimmune diseases (3 cohorts), sponsored by Hengrui. Primary endpoint: Safety and tolerability determined by adverse events at 4 days. Status: unknown.
02
Drugs
edralbrutinib
03
Conditions
B cell malignanciesautoimmune diseases
Beyond the preview
Go deeper on NCT03668509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668509.